Objective response rate assessment in oncology: Current situation and future expectations

Table 2 Comparison of modified Response Evaluation Criteria in Solid Tumors, European Association for the Study of the Liver and quantitative European Association for the Study of the Liver criteria for hepatocellular carcinoma[18,19,22-25]

	mRECIST (1D criteria)	EASL (2D criteria)	qEASL (3D criteria)
CR	Disappearance of any intratumoral enhancement in all target lesions	Disappearance of any intratumoral enhancement in all target lesions	Disappearance of any intratumoral enhancement in all target lesions
PR	At least 30% decrease in the sum of max. diameters of the enhanced tumor area	At least 50% decrease in the product of max. diameter and its perpendicular of the enhanced tumor area	At least 65% decrease in the enhanced tumor volume
SD	Neither PR, nor PD	Neither PR, nor PD	Neither PR, nor PD
PD	At least 20% increase in the sum of diameters of the enhanced tumor area	At least 25% increase in the product of max. diameter and its perpendicular of the enhanced tumor area	At least 73% increase in the enhanced tumor volume

EASL: European Association for the Study of the Liver; qEASL: Quantitative European Association for the Study of the Liver; HCC: Hepatocellular carcinoma; 1D: Unidimensional; 2D: Bidimensional; 3D: Tridimensional (volumetric); CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.